JPWO2017018542A1 - フコキサンチンを含有する抗糖化組成物 - Google Patents
フコキサンチンを含有する抗糖化組成物 Download PDFInfo
- Publication number
- JPWO2017018542A1 JPWO2017018542A1 JP2017531421A JP2017531421A JPWO2017018542A1 JP WO2017018542 A1 JPWO2017018542 A1 JP WO2017018542A1 JP 2017531421 A JP2017531421 A JP 2017531421A JP 2017531421 A JP2017531421 A JP 2017531421A JP WO2017018542 A1 JPWO2017018542 A1 JP WO2017018542A1
- Authority
- JP
- Japan
- Prior art keywords
- fucoxanthin
- composition
- glycation
- fucoxanthinol
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 title claims abstract description 71
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 108700028369 Alleles Proteins 0.000 claims abstract description 35
- NZEPSBGUXWWWSI-FWFPOGQTSA-N (3e,5e,7e,9e,11e,13e,15e)-18-[(2r,4s)-2,4-dihydroxy-2,6,6-trimethylcyclohexylidene]-1-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]-3,7,12,16-tetramethyloctadeca-3,5,7,9,11,13,15,17-octaen-2-one Chemical compound C([C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)C(=O)C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C=C=C1C(C)(C)C[C@H](O)C[C@@]1(C)O NZEPSBGUXWWWSI-FWFPOGQTSA-N 0.000 claims abstract description 30
- LBCWAKKSVZUJKE-YGQWAKCJSA-N fucoxanthinol Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)CC12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=C=C3C(O)CC(O)CC3(C)C LBCWAKKSVZUJKE-YGQWAKCJSA-N 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 208000002249 Diabetes Complications Diseases 0.000 claims abstract description 12
- 206010012655 Diabetic complications Diseases 0.000 claims abstract description 8
- 206010071602 Genetic polymorphism Diseases 0.000 claims abstract description 6
- 230000004043 responsiveness Effects 0.000 claims abstract description 6
- 210000004369 blood Anatomy 0.000 claims description 42
- 239000008280 blood Substances 0.000 claims description 42
- 108010004903 glycosylated serum albumin Proteins 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 7
- 230000032683 aging Effects 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 13
- 230000002255 enzymatic effect Effects 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 208000024891 symptom Diseases 0.000 abstract description 10
- 239000000047 product Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 11
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 10
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000036252 glycation Effects 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 101150022052 UCP1 gene Proteins 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000013600 Diabetic vascular disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 238000007397 LAMP assay Methods 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000007529 anxiety like behavior Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
(2)血中のHbA1c及び/又はグリコアルブミンの濃度の上昇を抑制する及び/又は前記濃度を低減させるための、(1)に記載の組成物。
(3)糖尿病及び/又は糖尿病合併症を処置するための、(1)又は(2)に記載の組成物。
(4)老化を処置するための、(1)に記載の組成物。
(5)食品組成物である、(1)から(4)のいずれかに記載の組成物。
(6)フコキサンチン、フコキサンチノール及び/又はその誘導体を含有する抗糖化組成物への応答性を判定する方法であって、該組成物の投与を予定している者について、米国バイオテクノロジー情報センター(NCBI)の遺伝子多型データベースに登録されているrs番号で示される遺伝子多型rs1800592におけるアレル対を特定する工程、及び前記アレル対がG/Gであるときにその者が前記抗糖化組成物に応答性であると判定する工程を含む、前記方法。
1)試験方法
北海道留萌地域在住のBMIが22以上である成人男女のうち、「フコキサンチンの機能性の探索」に関するヒト介入試験の実施について同意が得られた方60名を対象にし、無作為に、1日あたりのフコキサンチン投与量が0、1、2mg/日の3つのグループ(グループ0、1、2)に盲検化して割り付け、藻類であるアカモクから抽出したフコキサンチン(株式会社カネカ製フコキサンチンカプセル)を8週間にわたって経口投与した。これら3つのグループに関する年齢、性別その他のバックグラウンドは表2に示すとおりである。年齢、性別、BMIの他、評価項目においても有意な差はみられず、無作為化により3群に偏りなく割り付けられたことが確認できた。
試験参加者における生体内へのフコキサンチンの取り込みを確認するため、フコキサンチノールを含む血清エポキシキサントフィル画分をAsaiらの方法(Br J Nutr.2008;100(2):273−7)に基づいて抽出し、血清フコキサンチノール濃度を測定した。具体的には、試験参加者から採取された血清1mlに0.2ml生理食塩水及び5ngの内部標準フコキサンチンを含む2mlメタノールを添加、その後4mlのジクロロメタンを添加し、混和後遠心し下層を回収、この操作を2回繰り返した。下層を乾燥後、n−ヘキサン/ジエチルエーテル(9/1、v/v)に溶解し、n−ヘキサンで洗浄したBond Elute ALN(Agilent Technologies)に注入した。1ml n−ヘキサン/ジエチルエーテル(9/1、v/v)にて中性脂質やカロテン画分を除去した後、1ml ジエチルエーテル/エタノール(4/1、v/v)でエポキシキサントフィル画分を溶出、回収した。遠心乾燥後、メタノール/アセトニトリル(70/30、v/v)に溶解し液体クロマトグラフィー質量分析(LC/MS/MS)に用いた。
肝機能指標として選択したAST(アスパラギン酸アミノトランスフェラーゼ)、ALT(アラニンアミノトランスフェラーゼ)、γ−GTPのいずれも、3つのグループともフコキサンチン8週間の投与の前後で有意な差はみられなかった。
モデルマウスを用いた試験でフコキサンチンが血中コレステロール濃度を上昇させることが報告されているが、今回のヒト介入試験では、3つのグループとも、フコキサンチン8週間の投与の前後で総コレステロール、HDL−コレステロール及びLDL−コレステロールのいずれにおいても有意な差はみられなかった。
空腹時血糖値及びインスリンについては、3つのグループとも、フコキサンチン8週間の投与の前後で有意な差はみられなかったが、血中HbA1c濃度(%)については、グループ2(フコキサンチン投与量2mg/日)においてフコキサンチン8週間の投与の前後で有意に低減したことが確認された(図2)。
血中HbA1c濃度の変化とrs1800592におけるアレルとの関連性を検討した。グループ0及び1ではアレルによる血中HbA1c濃度の変化量に差は認められなかった(図3のGROUP0、GROUP1及び図4のGROUP=0、GROUP=1)が、グループ2(2mg/日投与群)ではA/Aアレル及びA/Gアレルに対し、G/Gアレルである試験参加者全員において血中HbA1c濃度が有意に低減していることが確認された(図3のGROUP2及び図4のGROUP=2)。なお、血中フコキサンチノール濃度については、グループ1及びグループ2いずれにおいてもアレルの違いによる差は認められなかった。
Claims (6)
- 1日あたり2mg以上のフコキサンチンに相当する量のフコキサンチン、フコキサンチノール及び/又はその誘導体が、米国バイオテクノロジー情報センター(NCBI)の遺伝子多型データベースに登録されているrs番号で示される遺伝子多型rs1800592におけるアレル対がG/Gである者に投与されるように用いられることを特徴とする、フコキサンチン、フコキサンチノール及び/又はその誘導体を含有する抗糖化組成物。
- 血中のHbA1c及び/又はグリコアルブミンの濃度の上昇を抑制する及び/又は前記濃度を低減させるための、請求項1に記載の組成物。
- 糖尿病及び/又は糖尿病合併症を処置するための、請求項1又は2に記載の組成物。
- 老化を処置するための、請求項1に記載の組成物。
- 食品組成物である、請求項1から4のいずれかに記載の組成物。
- フコキサンチン、フコキサンチノール及び/又はその誘導体を含有する抗糖化組成物への応答性を判定する方法であって、該組成物の投与を予定している者について、米国バイオテクノロジー情報センター(NCBI)の遺伝子多型データベースに登録されているrs番号で示される遺伝子多型rs1800592におけるアレル対を特定する工程、及び前記アレル対がG/Gであるときにその者が前記抗糖化組成物に応答性であると判定する工程を含む、前記方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015150319 | 2015-07-30 | ||
JP2015150319 | 2015-07-30 | ||
PCT/JP2016/072473 WO2017018542A1 (ja) | 2015-07-30 | 2016-08-01 | フコキサンチンを含有する抗糖化組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2017018542A1 true JPWO2017018542A1 (ja) | 2018-06-07 |
JP6749697B2 JP6749697B2 (ja) | 2020-09-02 |
Family
ID=57884379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017531421A Active JP6749697B2 (ja) | 2015-07-30 | 2016-08-01 | フコキサンチンを含有する抗糖化組成物 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6749697B2 (ja) |
WO (1) | WO2017018542A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007116980A1 (ja) * | 2006-04-07 | 2007-10-18 | National University Corporation Hokkaido University | 血糖値上昇抑制剤 |
WO2007138933A1 (ja) * | 2006-05-25 | 2007-12-06 | Fcc Horiuchi Co., Ltd. | 糖尿病治療剤 |
JP2010270021A (ja) * | 2009-05-19 | 2010-12-02 | Oriza Yuka Kk | Ucp遺伝子発現促進剤 |
JP2013129627A (ja) * | 2011-12-21 | 2013-07-04 | Hydrox Kk | フロロタンニン類の簡易な調製方法とその利用 |
-
2016
- 2016-08-01 WO PCT/JP2016/072473 patent/WO2017018542A1/ja active Application Filing
- 2016-08-01 JP JP2017531421A patent/JP6749697B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007116980A1 (ja) * | 2006-04-07 | 2007-10-18 | National University Corporation Hokkaido University | 血糖値上昇抑制剤 |
WO2007138933A1 (ja) * | 2006-05-25 | 2007-12-06 | Fcc Horiuchi Co., Ltd. | 糖尿病治療剤 |
JP2010270021A (ja) * | 2009-05-19 | 2010-12-02 | Oriza Yuka Kk | Ucp遺伝子発現促進剤 |
JP2013129627A (ja) * | 2011-12-21 | 2013-07-04 | Hydrox Kk | フロロタンニン類の簡易な調製方法とその利用 |
Non-Patent Citations (1)
Title |
---|
WOO M-N ET AL: "Fucoxanthin supplementation improves plasma and hepatic lipid metabolism and blood glucose concentra", CHEMICO-BIOLOGICAL INTERACTIONS, vol. 186(3), JPN6016035655, 2010, pages 316 - 322, ISSN: 0004256210 * |
Also Published As
Publication number | Publication date |
---|---|
JP6749697B2 (ja) | 2020-09-02 |
WO2017018542A1 (ja) | 2017-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Neumeister et al. | Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls | |
Tutunchi et al. | Expression of NF‐κB, IL‐6, and IL‐10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD—Combined effects of oleoylethanolamide supplementation and calorie restriction: A triple‐blind randomized controlled clinical trial | |
Takeda et al. | Influence of olive-derived hydroxytyrosol on the toll-like receptor 4-dependent inflammatory response of mouse peritoneal macrophages | |
Larsen et al. | Human Paneth cell α-defensin-5 treatment reverses dyslipidemia and improves glucoregulatory capacity in diet-induced obese mice | |
KR20220164079A (ko) | 이미다졸디펩티드를 포함하는 제제 | |
Dalbo et al. | Effects of age on serum hormone concentrations and intramuscular proteolytic signaling before and after a single bout of resistance training | |
EP3739068A1 (en) | Nanovesicles derived from faecalibacterium prausnitzii, and uses thereof | |
Mateo-Gallego et al. | An alcohol-free beer enriched with isomaltulose and a resistant dextrin modulates gut microbiome in subjects with type 2 diabetes mellitus and overweight or obesity: A pilot study | |
Park | Association between polygenetic risk scores related to sarcopenia risk and their interactions with regular exercise in a large cohort of Korean adults | |
Lin et al. | Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle | |
JP2021511497A (ja) | サルコペニア及びnad欠乏のリスクの予測及び階層化の方法 | |
US10337069B2 (en) | Method for diagnosing hepatic fibrosis | |
He et al. | Increasing fracture risk associates with plasma circulating microRNAs in aging people’s sarcopenia | |
Arefhosseini et al. | Myo-inositol supplementation improves cardiometabolic factors, anthropometric measures, and liver function in obese patients with non-alcoholic fatty liver disease | |
Khoo et al. | Prevalence and control of hypercholesterolaemia as defined by NCEP-ATPIII guidelines and predictors of LDL-C goal attainment in a multi-ethnic Asian population | |
Yen et al. | Identification of phenothiazine as an ETV1‑targeting agent in gastrointestinal stromal tumors using the Connectivity Map | |
Arefhosseini et al. | Expression of inflammatory genes, WBC-derived inflammatory biomarkers and liver function indices: Effects of myo-inositol supplementation in obese patients with NAFLD | |
JP6749697B2 (ja) | フコキサンチンを含有する抗糖化組成物 | |
Hama et al. | Metabolic complications in myotonic dystrophy type 1: A cross-sectional survey using the National Registry of Japan | |
Ren et al. | Novel Oxysterol Sulfates Alleviate Injured Liver Function and Decrease Mortality in Mouse Models | |
US12018337B2 (en) | Nano-vesicle derived from catenibacterium bacteria and use thereof | |
JP6588666B2 (ja) | イミダゾールジペプチドを含む剤 | |
Gonzalez et al. | Ulcerative colitis host-microbiome response to hyperbaric oxygen Therapy | |
Freedman et al. | Ischemic necrosis of the tongue: Report of a case | |
Abd El-Maksoud | Study of Adiponectin Promotor Methylation Status in Patients with Non Alcoholic Fatty Liver Disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180118 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190730 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200703 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200728 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200806 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6749697 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |